News Archives

Atreo Expands RTSM Capabilities for Precision Medicine Clinical Trials

Agile Functionality Address an Unmet Need Within Clinical Development

SAN FRANCISCO, June 27, 2024

Atreo, Inc., a Clinical Development technology company focused on modernizing and simplifying the RTSM delivery experience, recently launched groundbreaking precision medicine RTSM capabilities in support of a leading radiopharm organization to address an unmet need within the life sciences space, offering standard functionality to address the growing emergence of targeted therapeutics.

“Atreo’s team has collaborated with several precision medicine sponsor organizations in recent months, and it became clear that an agile RTSM solution to support the nuances of their studies did not exist,” said Ryan Harrison, Atreo CEO. “Given the efficacy of targeted therapies and increasing frequency of these study designs, our team made a strategic decision to build standard RTSM functionality to support the requirements of such protocols. Rather than develop a standalone custom system to support our partner, we followed Atreo’s product methodology by embedding all precision medicine features into our core product.”

“RTSM systems have historically lacked out of the box, configurable functionality to support precision medicine, radiopharm, and cell | gene therapy trials,” said Jon Ball, Atreo COO. “Atreo’s unique functionality, built within our next generation Studio RTSM configuration platform, allows precision medicine RTSM solutions to be seamlessly delivered via 100% configuration, ensuring a quality profile that has proven historically challenging to maintain when building bespoke systems.”

Atreo’s future RTSM product releases will expand upon its personalized medicine solutions. “Precision medicine focused clinical teams have embraced the guidance of Atreo’s team on how to deliver a simplified, intuitive solution for the unique workflows of their trial designs,” said Brian Dunton, Atreo’s Head of Client Services. “We encourage all precision medicine focused sponsors to collaborate with Atreo’s team on how our RTSM solution can be leveraged to streamline their experiences.”

About Atreo (https://atreo.io)

Atreo is a Clinical Technology company, comprised of experienced Clinical Technology experts, that offers the next generation of RTSM platform. Atreo helps Clinical Teams to modernize the RTSM experience with unmatched agility and simplicity by leveraging advanced technology and testing methods. Atreo has addressed all common RTSM pain points. Our solution offers numerous advantages, with a specific emphasis on:

Speed: 1 – 2 week RTSM build from Kickoff to Go-Live
Quality Quantified: Modern testing practices mitigating RTSM risk
Agility: Simplified system changes at no cost and unmatched quality

Arrival of Studio v1.7 Marks Atreo’s Most Expansive Product Release

Atreo’s Next Generation RTSM Features on Display at Informa IRT 2024

San Francisco, CA, October 14, 2024

Atreo, Inc., a next generation Clinical Development SaaS company focused on modernizing and simplifying the RTSM delivery experience, announces the arrival of our most comprehensive product release to date, focused on expansion of Clinical Supplies management tools and enhancements to our in-platform collaboration tool, further streamlining the RTSM build and UAT experiences for Atreo’s client partners.

“As Atreo’s client portfolio continues to grow, we’ve been so fortunate to collaborate with clients and industry experts who have generously shared their expertise and invested in our ongoing refinement of our products,” said Rebecca Stone, Senior Director of Product at Atreo. “Customer feedback has always been at the core of our approach to enhancing RTSM features. Our recent v1.6 and v1.7 Studio releases were thoughtfully curated in close partnership with experienced Clinical Supplies professionals, with a focus on streamlining IP management and simplifying the RTSM experience for sites users.”

“Since joining Atreo, I’ve been incredibly impressed by the thoughtful advancements the team has integrated into our Studio platform,” said Evan Hahn, Atreo’s newly appointed Head of Global Sales. “The platform’s agility and expansive configurable options have far surpassed my lofty expectations. This is the RTSM solution I’ve been championing since entering the field 15 years ago. Our v1.7 release marks another significant step towards modernizing the RTSM experience for both Atreo’s clients and our internal teams.”

About Atreo: https://atreo.io

Atreo is a Clinical Technology company and a top destination of RTSM experts, that has created the next generation RTSM platform.  Atreo helps Clinical Teams to modernize the RTSM experience with unmatched agility and simplicity by leveraging advanced technology and testing methods. Atreo has addressed all common RTSM pain points.  Our solution offers numerous advantages, with a specific emphasis on:

Speed:  1 – 2 week RTSM build from Kickoff to Go-Live

Quality Quantified:  Modern testing practices mitigating RTSM risk

Agility:  Simplified system changes at no cost and unmatched quality

Atreo Welcomes Jon Dole and Mark Paiz as New Board Members

New Board Appointees Bolster Atreo’s Seasoned Executive Team

SAN FRANCISCO, July 24, 2023 /PRNewswire/ — Atreo, Inc., a next-generation RTSM technology company, is thrilled to announce the appointment of two new distinguished board members, Jon Dole and Mark Paiz, who bring a wealth of industry experience to our organization. The decision was finalized during Atreo’s Annual Stockholder’s Meeting held on July 19, 2023.

Jon and Mark’s appointment to Atreo’s board fortifies the company’s strategic direction with extensive industry knowledge and exceptional accomplishments in the RTSM / IRT / Clinical Supplies domains. Their addition to the board marks a pivotal moment in Atreo’s journey, further solidifying its position as a technology leader in RTSM space.

Jon and Mark’s deep expertise of our industry and scaling technology companies will surely bolster Atreo’s growth plans.

Jon Dole is a RTSM visionary and successful entrepreneur. Jon has founded multiple RTSM companies and has been instrumental in driving Atreo’s innovation focus. His strategic vision and deep understanding of the RTSM space will undoubtedly complement Atreo’s growth objectives.

Mark Paiz is a seasoned Life Sciences Technology executive and entrepreneur, bringing several decades of experience to Atreo, having held prominent leadership roles at both startups and Fortune 500 organizations. His insights into scaling technology organizations and Clinical Supplies experience make him an invaluable asset to Atreo.

“We are thrilled to welcome Jon and Mark to Atreo’s Board of Directors. Their impressive track records and deep understanding of our industry will significantly enhance our ability to chart a successful course for the future,” said Ryan Harrison, CEO of Atreo. “Both Mark and Jon have been actively providing their expertise and guidance since Atreo’s founding, demonstrating their dedication to our mission from day one. Their commitment to the organization’s values and vision makes them an ideal fit to support Atreo’s continued growth.”

About Atreo:

Atreo is a modern RTSM company, comprised of experienced clinical technology experts, that has created the next generation of RTSM platform. Atreo helps clinical teams to modernize the RTSM experience with unmatched agility and simplicity by leveraging advanced technology and testing practices. Atreo has solved all common RTSM challenges, offering numerous advantages, with a specific emphasis on:

Speed: 1 – 2 Week RTSM build from Kickoff to Launch
Collaborative RTSM Design: RTSM configured prior to Kickoff Meeting
Agility: System changes at no cost and unmatched quality

SOURCE Atreo, Inc.

Atreo’s v1.2 Release to be Presented at SCOPE 2023, February 7-8th in Orlando

Greetings,

Atreo’s seasoned team of RTSM experts continues to set new standards in terms of what can be accomplished by leveraging modern technology. Our new v1.2 release, featuring several refinements based on client feedback and internal expertise, will be showcased at SCOPE 2023 in Orlando next week. This release builds upon our already robust Studio configuration tool, helping to further simplify our client engagements and offer control of your clinical supply strategies in ways uncommon of legacy RTSM providers.

Our commitment is to streamline the RTSM delivery process, provide a collaborative and unique system design experience, and always prioritize the knowledge and expertise of our Atreo’s RTSM experts as the cornerstone of our client relationships. We are proud to say that our clients share this sentiment and can attest to the benefits of Atreo’s approach.

Atreo’s team of RTSM SMEs will be at Booth 334 at SCOPE, February 7th & 8th. Please reach out to our Business Development Team to set up a demo of the latest advancements in RTSM technology: contact@atreo.io

Excited to see you all in Orlando!

Ryan Harrison

CEO

Atreo PR Newswire Press Release

Atreo Secures $4M Funding Led by RTSM Veterans and SaaS Visionaries

Greetings-

Today marks an amazing milestone for Atreo. I am excited to share closing of our 2^nd fund raising round, providing the necessary capital to support our current and prospective clients and further advancements to our next generation RTSM platform. Thank you to all investors who took part in this round, many of whom chose to reinvest in Atreo based on our progress to date and confidence in our team.

To say I am proud of what we have accomplished over the past year is a huge understatement. We have been so fortunate to align with driven, inquisitive, and collaborative Atreo team members who share our values and vision for what can be accomplished by leveraging new technology with an open mind.

Atreo’s commercial launch has been overwhelmingly well received. Our initial client partners have recognized first-hand the many benefits of our approach, collaborative delivery, simplicity of our platform and the time saved in comparison to the industry norm. We are truly grateful for their enthusiasm to embrace an emerging technology company.

“Now that I have worked with Atreo, there is no reason to explore another RTSM provider.”
Atreo’s 1st Client | Head of Clinical Operations

Stay tuned for exciting updates in the weeks to come!

Ryan Harrison
CEO

Atreo PR Newswire Press Release

USDM’s Cloud Assurance Certification is THE Badge of Trust for Life Sciences Companies When Selecting Technology Vendors

SANTA BARBARA, CALIFORNIA — July 12, 2022 — USDM Life Sciences (USDM) announces its Cloud Assurance Certification program designed to help pharmaceutical, biotechnology, and medical device organizations make the best technology decisions to meet the regulatory requirements of health authorities worldwide.

Cloud Assurance Certified technology vendors must undergo rigorous assessments and demonstrate compliance with consolidated global health authority statutory and regulatory requirements. To become Cloud Assurance Certified, USDM performs a comprehensive and independent assessment of compliance, security, and data integrity, including technology, design validation, development, testing, qualification, maintenance methodologies, and processes to develop the infrastructure and regulated functionality.

USDM uses its proprietary Unified Compliance Matrix to identify relevant global regulations and standards that life sciences customers are required to meet, including the U.S. Food and Drug Administration (FDA)’s 21 CFR Part 11 and predicate rules, the European Union (EU)’s Annex 11, General Data Protection Regulation (GDPR), Health Canada, and the Australian Government Department of Health Therapeutic Goods Administration (TGA).

“We are thrilled to announce that several technology vendors have achieved their Cloud Assurance Certification in the last month,” said Kevin Brown, CEO of USDM. “Google Cloud, QAD, Oracle Supply Chain Management (SCM), Atreo.io, and Assent have demonstrated their commitment to advancing their life sciences customers and accelerating innovation. As technology providers enhance quality processes and testing coverage, life science companies benefit from a decreased cost of compliance, better risk management, and increased use of advanced technology. Cloud Assurance Certified is the proof; everyone wins – the technology developer, the scientist, and most importantly, the patient.”

Cloud Assurance Certified vendors must also pass a series of post-release compliance testing and release management assessment activities performed by USDM to maintain continuous compliance.

As part of the program, certified vendors receive audit-ready documents for their customers to leverage as regulatory evidence, including a Vendor Assurance Report and a Vendor Audit. Additionally, USDM offers its flagship Cloud Assurance subscription to ensure validation and release management achieve continuous compliance with certified vendors.

USDM Cloud Assurance Certified auditors are independent, non-governmental, global teams who confirm health authority statutory and regulatory requirements to ensure quality, safety, and intended use of technology solutions worldwide.

Learn more about becoming Cloud Assurance Certified.

About USDM Life Sciences

At USDM Life Sciences, our purpose is to bring clarity and action to the interplay of technology and regulations to help biotech, pharma, and medical device companies deliver trailblazing outcomes. We help our customers use cutting-edge technology to increase their speed to market while ensuring continuous compliance and patient safety. For more information, visit www.usdm.com.

Follow us on LinkedIn

Please follow Atreo on LinkedIn for updates on our platform, open roles, team growth and conference attendance!

Click here to follow Atreo .io